株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺癌診断・低侵襲治療市場

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

発行 Datamonitor Healthcare 商品コード 911321
出版日 ページ情報 英文 149 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
前立腺癌診断・低侵襲治療市場 Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
出版日: 2019年07月10日 ページ情報: 英文 149 Pages
概要

当レポートでは、前立腺癌診断・低侵襲治療市場における主要製品、新技術、市場予測、市場成長の促進要因・抑制要因、競合企業、および動向・機会などについて分析しています。

エグゼクティブサマリー

第1章 前立腺癌の概要

  • 病期
  • 発症率:米国、EU5ヶ国、日本
  • リスク要因
  • 検出・診断
  • 前立腺癌の治療法
    • 外科手術
    • 部分治療
    • 化学療法
    • 放射線療法
    • ホルモン療法
    • 生物学的療法
  • 参考資料

第2章 前立腺癌の診断

  • PSA検査
  • 分子診断・リキッドバイオプシー製品
  • バイオプシーガイダンスシステム
  • 前立腺癌診断製品市場
  • 参考資料

第3章 低侵襲前立腺癌治療

  • 前立腺癌手術
  • 前立腺放射線療法
    • EBRT
    • 近接照射療法
    • 放射線治療向けハイドロゲルスペーサー
  • 前立腺癌の切除
    • 冷凍アブレーション
    • 高密度焦点式超音波治療法
    • 不可逆電気穿孔法 (IRE)
  • 低侵襲前立腺癌治療市場
    • 市場額
    • セグメントの考察
    • 地域の考察
    • 市場動向
    • 市場成長の促進要因・抑制要因
    • 市場リーダー
  • 参考資料
  • 付録

付録A:企業リスト

目次

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends & opportunities in the nearly $1bn Prostate Cancer Diagnostics and Minimally Invasive Treatments market.

Table of Contents

Executive Summary

  • i. Prostate cancer overview
  • ii. Prostate cancer diagnostics and minimally invasive treatments market
    • a. Market drivers and limiters
    • b. Technology trends
    • c. Market leaders
    • d. Competitive strategies
    • e. Emerging competition
  • iii. Methodology
  • iv. Bibliography
  • Exhibit ES-1: Prostate cancer diagnostic products, global market forecast 2018-23
  • Exhibit ES-2: Minimally invasive prostate cancer treatments, global market forecast 2018-23

1. Prostate Cancer Overview

  • 1.1 Staging
  • 1.2 Incidence: US, 5EU and Japan
  • 1.3 Risk factors
    • 1.3.1 Genetics
  • 1.4 Detection and diagnosis
    • 1.4.1 PSA testing
    • 1.4.2 Screening
    • 1.4.3 Biopsy
    • 1.4.4 Molecular diagnostics and liquid biopsy
  • 1.5 Prostate Cancer Treatment pathways
    • 1.5.1 Surgery
    • 1.5.2 Focal therapies
    • 1.5.3 Chemotherapy
    • 1.5.4 Radiation therapy
    • 1.5.5 Hormonal therapy
    • 1.5.6 Biological treatments
  • 1.6 Bibliography
  • Exhibit 1-1: Estimated new cases of prostate cancer by stage, US, 2018 and 2023
  • Exhibit 1-2: Estimated new cases of prostate cancer by stage, 5EU, 2018 and 2023
  • Exhibit 1-3: Estimated new cases of prostate cancer by stage, Japan, 2018 and 2023
  • Exhibit 1-4: Advantages and disadvantages of multiparametric MRI for prostate imaging
  • Exhibit 1-5: Advantages and disadvantages of liquid biopsy
  • Exhibit 1-6: Treatment options for prostate cancer by cancer type/stage
  • Exhibit 1-7: Surgical options for prostate cancer
  • Exhibit 1-8: HIFU for prostate cancer using the transrectal approach
  • Exhibit 1-9: Advantages/disadvantages of HIFU for prostate cancer treatment
  • Exhibit 1-10: Advantages/disadvantages of IRE for prostate cancer treatment

2. Prostate Cancer Diagnostics

  • 2.1 PSA tests
  • 2.2 Molecular diagnostic and liquid biopsy products
  • 2.3 Biopsy guidance systems
    • 2.3.1 Emerging biopsy products/technologies
  • 2.4 Prostate cancer diagnostic products market
    • 2.4.1 Global market insights
    • 2.4.2 Market value
    • 2.4.3 Segment insights
    • 2.4.4 Regional insights
    • 2.4.5 Market trends
    • 2.4.6 Market drivers and limiters
    • 2.4.7 Market share
  • 2.5 Bibliography
  • Exhibit 2-1: Selected molecular diagnostic/liquid biopsy products for prostate cancer
  • Exhibit 2-2: Selected commercially available MRI-US fusion biopsy systems for prostate cancer diagnosis
  • Exhibit 2-3: Prostate cancer diagnostic products, combined market forecast, by product segment, 2018-23
  • Exhibit 2-4: Prostate cancer diagnostic products, US market forecast, 2018-2023
  • Exhibit 2-5: Prostate cancer diagnostic products, 5EU market forecast, 2018-2023
  • Exhibit 2-6: Prostate cancer diagnostic products, Japan market forecast, 2018-2023
  • Exhibit 2-7: Prostate cancer diagnostic products, RoW market forecast, 2018-2023
  • Exhibit 2-8: 2018, Prostate cancer diagnostic products market, share by supplier

3. Minimally Invasive Prostate Cancer Treatments

  • 3.1 Prostate cancer surgery
    • 3.1.1 Robotic-assisted laparoscopic prostatectomy (RALP) products
  • 3.2 Prostate radiation therapy
    • 3.2.1 EBRT
    • 3.2.2 Brachytherapy
    • 3.2.3 Hydrogel spacers for radiotherapy
  • 3.3 Ablation of prostate cancer
    • 3.3.1 Cryoablation
    • 3.3.2 High-intensity focused ultrasound
    • 3.3.3 Irreversible electroporation (IRE)
  • 3.4 Minimally invasive prostate cancer treatments market
    • 3.4.1 Market value
    • 3.4.2 Segment insights
    • 3.4.3 Regional insights
    • 3.4.4 Market trends
    • 3.4.5 Market drivers and limiters
    • 3.4.6 Market leaders
  • 3.5 Bibliography
  • 3.6 Appendix
    • 3.6.1 Prostate cancer ablation survey
  • Exhibit 3-1: Minimally invasive prostate cancer treatments, combined market forecast, by product segment 2018-2023
  • Exhibit 3-2: Minimally invasive prostate cancer treatments, US market forecast, 2018-2023
  • Exhibit 3-3: Minimally invasive prostate cancer treatments, 5EU market forecast, 2018-2023
  • Exhibit 3-4: Minimally invasive prostate cancer treatments, Japanese market forecast, 2018-2023
  • Exhibit 3-5: Minimally invasive prostate cancer treatments, RoW market forecast, 2018-2023
  • Exhibit 3-6: Minimally invasive prostate cancer treatments, forecast by region, 2018-2023
  • Exhibit 3-7: 2018, Minimally invasive prostate cancer treatments, share by supplier

Appendix A: company listing